Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
During a rebalance, which tax lots remain, get sold, or new lots form can shift. This intro explains the typical changes and implications.
20,499 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A seasoned CEO message can move markets, especially in AI era. This deep dive explains what broadcom hock just delive...
Palantir has sparked debate among investors with rapid growth and high expectations. This guide breaks down whether p...
Coty is navigating a shifting beauty market. This guide breaks down coty (coty) 2026 earnings, what the Q3 transcript...
Veteran investor Mark Kvamme is rolling out a Temasek style OHIO Fund, a $500 million vehicle aimed at accelerating g...
A famous endorsement pulled ordinary investors into a wild crypto ride, ending in legal battles and hard lessons. Thi...
As the first-quarter report for Innovate lands, investors eye more than just the top line. This guide breaks down wha...
An experienced investment banker explains why pension funds stick with complex alternatives even when a simple 60/40 ...
Quantum stocks are notoriously volatile. This guide explains why d-wave quantum stock keeps rising, what it means for...
Investors are watching Micron’s rally with curiosity. This guide explains why micron stock keeps going, what drives t...
A little-known semiconductor company just won EY’s World Entrepreneur of the Year in Monaco, signaling a new era of r...
When Vera Rubin Observatory updates hit the wires, NVIDIA often rallies on AI and data-center hype. Yet today’s marke...